Sino Biopharmaceutical (HKSE:01177) Other Current Payables : HK$2,782 Mil (As of Dec. 2023)

View and export this data going back to 2003. Start your Free Trial

What is Sino Biopharmaceutical Other Current Payables?

Sino Biopharmaceutical's Other Current Payables for the quarter that ended in Dec. 2023 was HK$2,782 Mil.

Sino Biopharmaceutical's quarterly Other Current Payables increased from Dec. 2022 (HK$2,151 Mil) to Jun. 2023 (HK$15,326 Mil) but then declined from Jun. 2023 (HK$15,326 Mil) to Dec. 2023 (HK$2,782 Mil).

Sino Biopharmaceutical's annual Other Current Payables increased from Dec. 2021 (HK$1,937 Mil) to Dec. 2022 (HK$2,151 Mil) and increased from Dec. 2022 (HK$2,151 Mil) to Dec. 2023 (HK$2,782 Mil).

Sino Biopharmaceutical Other Current Payables Historical Data

The historical data trend for Sino Biopharmaceutical's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sino Biopharmaceutical Other Current Payables Chart

Sino Biopharmaceutical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Current Payables

Get a 7-Day Free Trial

1,845.70

3,509.95

1,936.64

2,150.53

2,781.86

Sino Biopharmaceutical Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Other Current Payables	Get a 7-Day Free Trial															1,936.64	10,846.72	2,150.53	15,326.19	2,781.86

Sino Biopharmaceutical Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Sino Biopharmaceutical Other Current Payables Related Terms

Thank you for viewing the detailed overview of Sino Biopharmaceutical's Other Current Payables provided by GuruFocus.com. Please click on the following links to see related term pages.

Sino Biopharmaceutical (HKSE:01177) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sino Biopharmaceutical Ltd (HKSE:01177) » Definitions » Other Current Payables

Comparable Companies

Traded in Other Exchanges

SBHMY:USA SBMFF:USA SMZ1:Germany

Address

1 Harbour Road, Unit 09, 41st Floor, Office Tower, Room 4109, Convention Plaza, Wanchai, Hong Kong, HKG

Website

https://www.sinobiopharm.com

Sino Biopharmaceutical Co, or SBP, is one of the largest drugmakers in China, with CNY 27 billion revenue in 2021. Its four most important therapeutic areas are oncology, hepatitis, cardio-cerebral, and respiratory medicines. SBP's current portfolio is mostly generics, and some key drugs are facing severe price reductions. However, it also has a rich pipeline of early-to-market generics and biosimilars, especially in oncology and respiratory treatments.

Executives

Tse Eric S Y	2101 Beneficial owner
Tse Ping	2101 Beneficial owner
Cheng Cheung Ling	2101 Beneficial owner
True Merit Global Limited	2101 Beneficial owner
Tse Theresa Y Y	2101 Beneficial owner
Thousand Eagles Limited	2101 Beneficial owner
France Investment (china 1) Group Limited	2101 Beneficial owner
Remarkable Industries Limited	2101 Beneficial owner
Validated Profits Limited	2101 Beneficial owner

Sino Biopharmaceutical (HKSE:01177) Headlines

No Headlines